Drug Trial Radar · NCT06836232
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 28, 2025
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Zomagen Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period Cohort C will include approximately 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period
Conditions
- Recurrent Pericarditis
Interventions
VTX2735Drug
Dose A, Daily
VTX2735Drug
Dose B, Daily
VTX2735Drug
Dose C, Daily
VTX2735Drug
Dose D, Daily
VTX2735Drug
Dose E, Daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of VTX2735Time frame: Day 1 of treatment period through study completion, up to 26 weeks
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Site Location #840023
La Jolla, California · Recruiting
Local Site #840014
Orange, California · Recruiting
Local Site #840016
Saint Augustine, Florida · Recruiting
Local Site #840008
Chicago, Illinois · Recruiting
Local Site #840010
Boston, Massachusetts · Recruiting
Local Site #840005
Rochester, Minnesota · Recruiting
Local Site #840020
New York, New York · Recruiting
Local Site #840017
Cleveland, Ohio · Recruiting
Local Site #840019
Houston, Texas · Recruiting
Local Site #840001
Houston, Texas · Recruiting
Local Site #840013
Salt Lake City, Utah · Recruiting
Local Site #840022
Burlington, Vermont · Recruiting
Local Site #840004
Richmond, Virginia · Recruiting
Local Site #840018
Richmond, Virginia · Recruiting
Local Site #840021
Seattle, Washington · Recruiting
Local Site #056001
Ghent, Belgium · Recruiting
Local Site #056002
Leuven, Belgium · Recruiting
Local Site #840102
Montreal, Canada · Not yet recruiting
Local Site #840101
Ottawa, Canada · Recruiting
Local Site #300001
Athens, Greece · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.